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Middle East respiratory syndrome (MERS) is a deadly viral respiratory disease caused by 
MERS- coronavirus (MERS-CoV) infection. To date, there is no specific treatment proven 
effective against this viral disease. In addition, no vaccine has been licensed to prevent 
MERS-CoV infection thus far. Therefore, our current review focuses on the most recent 
studies in search of an effective MERS vaccine. Overall, vaccine candidates against MERS-
CoV are mainly based upon the viral spike (S) protein, due to its vital role in the viral 
infectivity, although several studies focused on other viral proteins such as the nucleocapsid 
(N) protein, envelope (E) protein, and non-structural protein 16 (NSP16) have also been 
reported. In general, the potential vaccine candidates can be classified into six types: viral 
vector-based vaccine, DNA vaccine, subunit vaccine, nanoparticle-based vaccine, inactivated-
whole virus vaccine and live-attenuated vaccine, which are discussed in detail. Besides, the 
immune responses and potential antibody dependent enhancement of MERS-CoV infection 
are extensively reviewed. In addition, animal models used to study MERS-CoV and evaluate 
the vaccine candidates are discussed intensively. 
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